Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Progress in the treatment of neuroendocrine tumors.

Chan JA, Kulke MH.

Curr Oncol Rep. 2009 May;11(3):193-9. Review.

2.

[More attention should be paid to the understanding of gastroenteropancreatic neuroendocrine tumors].

Xu JM.

Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):158-60. doi: 10.3760/cma.j.issn.0253-3766.2012.02.018. Chinese. No abstract available.

PMID:
22780939
3.

[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].

Ito T, Igarashi H, Jensen RT, Takayanagi R.

Fukuoka Igaku Zasshi. 2012 Jul;103(7):131-7. Review. Japanese. No abstract available.

PMID:
22978065
4.

Perspectives in the development of novel treatment approaches.

Yao JC, Catena L, Colao A, Paganelli G.

Tumori. 2010 Sep-Oct;96(5):858-73. No abstract available.

PMID:
21302643
5.

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.

Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S87-94. doi: 10.1016/S0305-7372(10)70026-8. Review.

PMID:
21129617
6.

Digestive neuroendocrine tumors (DNET): the era of targeted therapies.

Boussaha T, Rougier P, Taieb J, Lepere C.

Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):134-41. doi: 10.1016/j.clinre.2012.09.010. Epub 2013 Apr 3. Review.

PMID:
23562338
7.

Recent studies show promise for treating rare pancreatic tumors.

Peres J.

J Natl Cancer Inst. 2011 Apr 20;103(8):624-7. doi: 10.1093/jnci/djr140. Epub 2011 Apr 7. No abstract available.

PMID:
21474831
8.

[Drug therapy for neuroendocrine tumours].

Tóth M.

Orv Hetil. 2013 Sep 29;154(39):1556-64. doi: 10.1556/OH.2013.29718. Review. Hungarian.

PMID:
24058101
9.

Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?

Reidy-Lagunes D, Thornton R.

Curr Oncol Rep. 2012 Jun;14(3):249-56. doi: 10.1007/s11912-012-0232-1. Review.

PMID:
22434313
10.

Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.

Raj N, Reidy-Lagunes D.

Pancreas. 2014 Nov;43(8):1185-9. doi: 10.1097/MPA.0000000000000232. Review.

PMID:
25333401
11.

Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

Mateo J, Heymach JV, Zurita AJ.

Mol Diagn Ther. 2012 Jun 1;16(3):151-61. doi: 10.2165/11632590-000000000-00000. Review.

12.

New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

Eriksson B.

Curr Opin Oncol. 2010 Jul;22(4):381-6. doi: 10.1097/CCO.0b013e32833adee2. Review.

PMID:
20473165
13.

New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?

Raymond E, Ruszniewski P.

Target Oncol. 2012 Jun;7(2):91-2. doi: 10.1007/s11523-012-0222-0. Epub 2012 Jun 5. No abstract available.

PMID:
22669625
14.

New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.

Weber M.

Clin Adv Hematol Oncol. 2014 Dec;12(12 Suppl 19):12-7. Review. No abstract available.

PMID:
25768104
15.

Systemic therapy for advanced pancreatic neuroendocrine tumors.

Kulke MH.

Semin Oncol. 2013 Feb;40(1):75-83. doi: 10.1053/j.seminoncol.2012.11.010. Review.

16.

[Recent progress in the molecular-targeting treatment of neuroendocrine tumors].

Unno M.

Nihon Shokakibyo Gakkai Zasshi. 2010 Mar;107(3):392-5. Review. Japanese. No abstract available.

PMID:
20203442
17.

Targeted agents in treatment of neuroendocrine tumors of pancreas.

Karampelas IN, Syrigos KN, Saif MW.

JOP. 2014 Jul 28;15(4):351-3. doi: 10.6092/1590-8577/2694. Review.

18.
19.

Neuroendocrine tumors: treatment updates.

Khagi S, Saif MW.

JOP. 2013 Jul 10;14(4):367-71. doi: 10.6092/1590-8577/1657.

20.

Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.

Crippa S, Partelli S, Boninsegna L, Falconi M.

Ann Oncol. 2012 Jul;23(7):1928. doi: 10.1093/annonc/mds166. No abstract available.

PMID:
22753260

Supplemental Content

Support Center